Back to search results

AI for Endometrial Cancer Detection in Post-Menopausal Bleeding

This study is looking at whether artificial intelligence (AI) can help identify endometrial cancer or pre-cancerous changes using images from a transvaginal ultrasound (an internal ultrasound). You may be able to join if you are a woman aged 55 or older who has experienced post-menopausal bleeding and has had an endometrial biopsy available from Mayo Clinic or an external institution. The study aims to see how accurate the AI algorithm is at detecting these conditions. This is an observational study, meaning researchers will collect information without giving you a specific treatment. The current recruitment status is unclear.

Study design
This is an observational study planning to include 300 women. It is not a randomized trial, meaning participants will not be assigned to different treatment groups.
What's involved
You will undergo a transvaginal ultrasound and endometrial sampling as part of your usual care. Researchers will also review your medical records.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to measure the AI algorithm's accuracy at baseline, so long-term follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06365905

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

Recruiting
Not specifiedAges 55+Observational
Mayo Clinic
~300 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Accuracy of artificial intelligence (AI) algorithm applied to transvaginal ultrasound (TVUS)
Measured over Baseline

Conditions

Endometrial Carcinoma

Explore related trials

Endometrial Carcinoma

Where it's being run

3 sites across 3 states
Arizona1
Florida1
Minnesota1

Study leadership

  • Gretchen E Glaser, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 55 years
At least one episode of postmenopausal bleeding (PMB)
Endometrial biopsy available from at Mayo Clinic (MN, AZ, FL), Mayo Clinic Health System (MCHS), or an external institution
Acceptance to participate in the study

Exclusion

Diagnostic tests performed more than 90 days apart
Physical impediment/refusal to undergo transvaginal ultrasound (TVUS)

What this trial measures

  • Accuracy of artificial intelligence (AI) algorithm applied to transvaginal ultrasound (TVUS)Baseline

    Two static TVUS images (one longitudinal, one transversal) will be independently validated and compared to results of endometrial sampling. Outcomes from these will be compared with predictions made by the AI models for accuracy of assessing premalignant/malignant disease.